Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Royalty Pharma
Biotech
Biogen taps Royalty for $250M to fund phase 3 lupus program
The cash will bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of assets with potential peak sales of $14 billion.
Nick Paul Taylor
Feb 12, 2025 8:10am
Investors say 'no bueno' to Cytokinetics' complex Royalty deal
May 23, 2024 10:36am
Karuna's new schizophrenia drug reaches FDA's desk
Sep 28, 2023 11:12am
Royalty swoops in with $100M upfront for slice of Karuna's KarXT
Mar 23, 2023 9:45am
Arrowhead fills quiver with $250M Royalty deal
Nov 9, 2022 11:00am
Merck gains Moderna's cancer shot, signs Royalty collab
Oct 12, 2022 10:55am
